Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of polo-like kinases, in preclinical models of acute myeloid Leukemia

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 3, 2015, Pages 579-589

  Rudolph, Dorothea ^a   Impagnatiello, Maria Antonietta ^a   Blaukopf, Claudia ^b   Sommer, Christoph ^b   Gerlich, Daniel W ^b   Roth, Mareike ^a   Tontsch Grunt, Ulrike ^a   Wernitznig, Andreas ^a   Savarese, Fabio ^a   Hofmann, Marco H ^a   Albrecht, Christoph ^a   Geiselmann, Lena ^a   Reschke, Markus ^a,c   Garin Chesa, Pilar ^a   Zuber, Johannes ^a   Moll, Jürgen ^a,c   Adolf, Günther R ^a   Kraut, Norbert ^a  

^a BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^b INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; HISTONE H3; NUCLEOPHOSMIN; QUIZARTINIB; VOLASERTIB; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL DENSITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; EC50; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PROMETAPHASE; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG SCREENING; ENZYMOLOGY; HELA CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; NUDE MOUSE; PROCEDURES; SCID MOUSE; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; CELL CYCLE PROTEINS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HELA CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; MICE, SCID; MICE, TRANSGENIC; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922362926     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.221150     Document Type: Article

References (32)

1. Christoph DC and Schuler M (2011) Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies. Expert Rev Anticancer Ther 11:1115-1130.
2. Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P., Hunt JP, Lasater EA, Pallares G, Picaud S., Wells C, et al. (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 10:305-312.
3. Cucchi U, Gianellini LM, De Ponti A, Sola F, Alzani R., Patton V, Pezzoni A, Troiani S., Saccardo MB, Rizzi S, et al. (2010) Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. Anticancer Res 30:4973-4985.
4. Demajo S, Uribesalgo I, Gutiérrez A, Ballaré C, Capdevila S, Roth M, Zuber J, Martín-Caballero J, and Di Croce L (2014) ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia. Oncogene 33: 5501-5510.
5. Dick AE and Gerlich DW (2013) Kinetic framework of spindle assembly checkpoint signalling. Nat Cell Biol 15:1370-1377.
6. Dohner H, Lubbert M, Fiedler W., Fouillard L, Haaland A, Brandwein J.M., Lepretre S., Reman O, Turlure P, Ottmann O.G., et al. (2014) Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 124:1426-1433.
7. Fenton B and Glover DM (1993) A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos. Nature 363:637-640.
8. Filippakopoulos P, Qi J, Picaud S., Shen Y, Smith WB, Fedorov O, Morse E.M., Keates T., Hickman TT, Felletar I, et al. (2010) Selective inhibition of BET bromodomains. Nature 468:1067-1073.
9. Gjertsen BT and Schoffski P (2015) Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 29:11-19.
10. Golsteyn RM, Mundt KE, Fry A.M., and Nigg EA (1995) Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 129:1617-1628.
11. Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A., Ried T, and Nigg EA (1994) Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 107:1509-1517.
12. Hamanaka R, Smith MR, O'Connor PM, Maloid S, Mihalic K., Spivak JL, Longo DL, and Ferris DK (1995) Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem 270:21086-21091.
13. Ikezoe T, Yang J, Nishioka C., Takezaki Y, Tasaka T, Togitani K., Koeffler HP, and Yokoyama A (2009) A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 23:1564-1576.
14. Janning M and Fiedler W (2014) Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Future Oncol 10:1157-1165.
15. Lénárt P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, Rettig WJ, Kraut N, and Peters JM (2007) The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 17:304-315.
16. Li D, Ambrogio L, Shimamura T., Kubo S, Takahashi M, Chirieac L.R., Padera RF, Shapiro GI, Baum A, Himmelsbach F., et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711.
17. Liu X and Erikson RL (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100:5789-5794.
18. Neumann B, Held M, Liebel U., Erfle H, Rogers P, Pepperkok R., and Ellenberg J (2006) High-throughput RNAi screening by time-lapse imaging of live human cells. Nat Methods 3:385-390.
19. Papavassiliou KA and Papavassiliou AG (2014) Bromodomains: pockets with therapeutic potential. Trends Mol Med 20:477-478.
20. Petronczki M, Lénárt P, and Peters JM (2008) Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell 14:646-659.
21. Renner AG, Dos Santos C, Recher C, Bailly C., Créancier L, Kruczynski A., Payrastre B, and Manenti S (2009) Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 114:659-662.
22. Rudolph D, Steegmaier M, Hoffmann M., Grauert M, Baum A, Quant J., Haslinger C, Garin-Chesa P, and Adolf GR (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15:3094-3102.
23. Schöffski P (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14:559-570.
24. Schöffski P, Awada A, Dumez H., Gil T, Bartholomeus S, Wolter P., Taton M, Fritsch H, Glomb P., and Munzert G (2012) A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48:179-186.
25. Steegmaier M, Hoffmann M, Baum A., Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, et al. (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316-322.
26. Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9:643-660.
27. Strebhardt K and Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6:321-330.
28. Sumara I, Giménez-Abián JF, Gerlich D, Hirota T, Kraft C, de la Torre C, Ellenberg J, and Peters JM (2004) Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 14:1712-1722.
29. Takai N, Hamanaka R, Yoshimatsu J., and Miyakawa I (2005) Polo-like kinases (Plks) and cancer. Oncogene 24:287-291.
30. Tsykunova G, Reikvam H, Ahmed A.B., Nepstad I., Gjertsen BT, and Bruserud Ø (2012) Targeting of polo-like kinases and their cross talk with Aurora kinases-possible therapeutic strategies in human acute myeloid leukemia? Expert Opin Investig Drugs 21:587-603.
31. Zitouni S, Nabais C, Jana S.C., Guerrero A., and Bettencourt-Dias M (2014) Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol 15:433-452.
32. Zuber J, Shi J, Wang E., Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J., Blatt K, Wunderlich M, et al. (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478:524-528.